Gilead Sciences | GILD - Cash And Equivalent

Stock Price
149.37
Daily Change
3.14 2.15%
Monthly
23.08%
Yearly
52.36%
Q1 Forecast
137.58

Gilead Sciences reported $5.14B in Cash and Equivalent for its fiscal quarter ending in June of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.63B 838M Sep/2025
Agios Pharmaceuticals USD 92.71M 11.84M Sep/2025
ALKERMES USD 616.45M 95.25M Sep/2025
Alnylam Pharmaceuticals USD 1.49B 376.56M Sep/2025
Amgen USD 9.13B 316M Dec/2025
Biogen USD 3.86B 1.1B Sep/2025
BioMarin Pharmaceutical USD 1.25B 36.29M Sep/2025
Bristol-Myers Squibb USD 15.73B 3.13B Sep/2025
Eli Lilly USD 9.79B 6.42B Sep/2025
Gilead Sciences USD 5.14B 2.78B Jun/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
Glaxosmithkline GBP 3.3B 303M Sep/2025
Incyte USD 2.93B 508.08M Sep/2025
J&J USD 18.23B 10.35B Sep/2025
Merck USD 18.17B 10.16B Sep/2025
Moderna USD 1.13B 147M Sep/2025
Neurocrine Biosciences USD 340.2M 76.2M Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Pfizer USD 1.34B 295M Sep/2025
PTC Therapeutics USD 672.62M 344.77M Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Sarepta Therapeutics USD 613.08M 102.48M Sep/2025
United Therapeutics USD 1.34B 253M Sep/2025
Vertex Pharmaceuticals USD 6.29B 95.8M Sep/2025